Tissue-resident NK cells do their own glandscaping.

In this issue of JEM, Sparano et al. (https://doi.org/10.

Development of 6-amido-4-aminoisoindolyn-1,3-diones as p70S6K1 inhibitors and potential breast cancer therapeutics.

Introduction: Many breast cancer therapeutics target the PI3K/AKT/mTOR oncogenic pathway. Development of resistance to the therapeutics targeting this pathway is a frequent occurrence. Therapeutics targeting p70S6K1, a downstream member of this pathway, have recently gained importance due to its critical role in all types of breast cancer and its status as a prognostic marker.

Associated factors for parent-reported otitis media in 12-month-old infants.

Objective: To report host-related and environmental factors associated with otitis media (OM), and compare the prevalence of OM in 12-month-old infants reported by parents with that predicted from audiological assessment results.

Design: A non-randomised, cross-sectional design was used. Data were collected via a parental questionnaire during children's audiology appointment at 12 months of age.

Physicians-in-training and advanced practice providers perceptions in managing perioperative obstructive sleep apnea: a multi-institutional survey.

Study Objectives: Physicians-in-training (residents, fellows) and Advanced Practice Providers (APPs) receive limited education on sleep disorders, including obstructive sleep apnea (OSA). They often assess patients first. We aimed to understand their views on OSA and screening for OSA in the perioperative period.

GLP-1 RECEPTOR AGONISTS USE AND INCIDENCE OF GLAUCOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS: GLP-1 receptor agonists use and incidence of glaucoma.

Introduction: In diabetics, glucagon-like peptide 1 (GLP-1) receptor agonists (RA) may protect against microvascular alterations and oxidative stress, both of which have been implicated in glaucoma. Multiple studies suggest a possible relation between GLP-1 RA use and the development of glaucoma. This study performs a systematic review of the literature regarding the incidence of glaucoma development in type 2 diabetes patients treated with GLP-1 receptor agonists compared to a control group.